Parathyroid Changes After RAI in Patients With Differentiated Thyroid Carcinoma

ObjectiveThe purpose of this study was to investigate parathyroid hormone (PTH), serum calcium, phosphorus, and 25-hydroxyvitamin D (25-OH-VD) changes before and after radioactive iodine (RAI) in differentiated thyroid carcinoma (DTC) patients at different time points.MethodsA total of 259 DTC patie...

Full description

Bibliographic Details
Main Authors: Liu Xiao, Wenjie Zhang, Hongmei Zhu, Yueqi Wang, Bin Liu, Rui Huang, Lin Li
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-05-01
Series:Frontiers in Endocrinology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fendo.2021.671787/full
id doaj-0f9e294ee296469dbd8e67a3330085d5
record_format Article
spelling doaj-0f9e294ee296469dbd8e67a3330085d52021-05-27T04:45:39ZengFrontiers Media S.A.Frontiers in Endocrinology1664-23922021-05-011210.3389/fendo.2021.671787671787Parathyroid Changes After RAI in Patients With Differentiated Thyroid CarcinomaLiu XiaoWenjie ZhangHongmei ZhuYueqi WangBin LiuRui HuangLin LiObjectiveThe purpose of this study was to investigate parathyroid hormone (PTH), serum calcium, phosphorus, and 25-hydroxyvitamin D (25-OH-VD) changes before and after radioactive iodine (RAI) in differentiated thyroid carcinoma (DTC) patients at different time points.MethodsA total of 259 DTC patients who received RAI were prospectively enrolled. We evaluated PTH, serum calcium, phosphorus, and 25-OH-VD levels at baseline pre-RAI, five days, six weeks, and six months post-RAI, respectively. We analyzed the risk factors of hypocalcemia at five days post-RAI.ResultsThe mean PTH, serum calcium and phosphorus values decreased five days post-RAI compared with pre-RAI (PTH 4.18 ± 1.23 pmol/L vs. 3.95 ± 1.41 pmol/L; calcium 2.27 ± 0.09 mmol/L vs. 2.20 ± 0.11 mmol/L; phosphorus 1.25 ± 0.17 vs. 0.98 ± 0.20 mmol/L, P < 0.05), and the differences were statistically significant. The mean 25-OH-VD levels did not significantly decrease at five days post-RAI. 21.2% (55/259) of patients had hypocalcemia at five days post-RAI, and all of them were given oral calcium supplements. At six weeks post-RAI, all of the above parameters were higher than those at five days post-RAI. Multivariate regression analysis showed that baseline pre-RAI serum calcium < 2.27 mmol/L, PTH < 4.18 pmol/L and negative 99mTcO4- thyroid imaging were risk factors for hypocalcemia at five days post-RAI.ConclusionFor DTC patients with normal PTH and serum calcium levels at pre-RAI, their PTH, serum calcium, and phosphorus levels decreased at five days post-RAI. About one-fifth of patients could have hypocalcemia at five days post-RAI. Lower baseline pre-RAI serum calcium and PTH levels and negative 99mTcO4- thyroid imaging were risk factors for hypocalcemia five days post-RAI.https://www.frontiersin.org/articles/10.3389/fendo.2021.671787/fulldifferentiated thyroid carcinomaparathyroid hormoneserum calciumserum phosphorusradioactive iodine
collection DOAJ
language English
format Article
sources DOAJ
author Liu Xiao
Wenjie Zhang
Hongmei Zhu
Yueqi Wang
Bin Liu
Rui Huang
Lin Li
spellingShingle Liu Xiao
Wenjie Zhang
Hongmei Zhu
Yueqi Wang
Bin Liu
Rui Huang
Lin Li
Parathyroid Changes After RAI in Patients With Differentiated Thyroid Carcinoma
Frontiers in Endocrinology
differentiated thyroid carcinoma
parathyroid hormone
serum calcium
serum phosphorus
radioactive iodine
author_facet Liu Xiao
Wenjie Zhang
Hongmei Zhu
Yueqi Wang
Bin Liu
Rui Huang
Lin Li
author_sort Liu Xiao
title Parathyroid Changes After RAI in Patients With Differentiated Thyroid Carcinoma
title_short Parathyroid Changes After RAI in Patients With Differentiated Thyroid Carcinoma
title_full Parathyroid Changes After RAI in Patients With Differentiated Thyroid Carcinoma
title_fullStr Parathyroid Changes After RAI in Patients With Differentiated Thyroid Carcinoma
title_full_unstemmed Parathyroid Changes After RAI in Patients With Differentiated Thyroid Carcinoma
title_sort parathyroid changes after rai in patients with differentiated thyroid carcinoma
publisher Frontiers Media S.A.
series Frontiers in Endocrinology
issn 1664-2392
publishDate 2021-05-01
description ObjectiveThe purpose of this study was to investigate parathyroid hormone (PTH), serum calcium, phosphorus, and 25-hydroxyvitamin D (25-OH-VD) changes before and after radioactive iodine (RAI) in differentiated thyroid carcinoma (DTC) patients at different time points.MethodsA total of 259 DTC patients who received RAI were prospectively enrolled. We evaluated PTH, serum calcium, phosphorus, and 25-OH-VD levels at baseline pre-RAI, five days, six weeks, and six months post-RAI, respectively. We analyzed the risk factors of hypocalcemia at five days post-RAI.ResultsThe mean PTH, serum calcium and phosphorus values decreased five days post-RAI compared with pre-RAI (PTH 4.18 ± 1.23 pmol/L vs. 3.95 ± 1.41 pmol/L; calcium 2.27 ± 0.09 mmol/L vs. 2.20 ± 0.11 mmol/L; phosphorus 1.25 ± 0.17 vs. 0.98 ± 0.20 mmol/L, P < 0.05), and the differences were statistically significant. The mean 25-OH-VD levels did not significantly decrease at five days post-RAI. 21.2% (55/259) of patients had hypocalcemia at five days post-RAI, and all of them were given oral calcium supplements. At six weeks post-RAI, all of the above parameters were higher than those at five days post-RAI. Multivariate regression analysis showed that baseline pre-RAI serum calcium < 2.27 mmol/L, PTH < 4.18 pmol/L and negative 99mTcO4- thyroid imaging were risk factors for hypocalcemia at five days post-RAI.ConclusionFor DTC patients with normal PTH and serum calcium levels at pre-RAI, their PTH, serum calcium, and phosphorus levels decreased at five days post-RAI. About one-fifth of patients could have hypocalcemia at five days post-RAI. Lower baseline pre-RAI serum calcium and PTH levels and negative 99mTcO4- thyroid imaging were risk factors for hypocalcemia five days post-RAI.
topic differentiated thyroid carcinoma
parathyroid hormone
serum calcium
serum phosphorus
radioactive iodine
url https://www.frontiersin.org/articles/10.3389/fendo.2021.671787/full
work_keys_str_mv AT liuxiao parathyroidchangesafterraiinpatientswithdifferentiatedthyroidcarcinoma
AT wenjiezhang parathyroidchangesafterraiinpatientswithdifferentiatedthyroidcarcinoma
AT hongmeizhu parathyroidchangesafterraiinpatientswithdifferentiatedthyroidcarcinoma
AT yueqiwang parathyroidchangesafterraiinpatientswithdifferentiatedthyroidcarcinoma
AT binliu parathyroidchangesafterraiinpatientswithdifferentiatedthyroidcarcinoma
AT ruihuang parathyroidchangesafterraiinpatientswithdifferentiatedthyroidcarcinoma
AT linli parathyroidchangesafterraiinpatientswithdifferentiatedthyroidcarcinoma
_version_ 1721425946324500480